The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Table 3 Relationship between CRP reduction and ACR response following ACZ885 treatment

Group	CRP reduction at day 43 versus baseline	ACR response at day 43
		<20%	20% to <50%	50% or more
10 mg/kg ACZ885	<20%	4	0	0
	20 to <50%	0	1	1
	50% or more	8	2	2
Placebo	<20%	9	1	0
	20 – <50%	2	0	0
	50% or more	3	0	0

Relationship between C-reactive protein (CRP) reduction and American College of Rheumatology (ACR) response at day 43 for patients in the 10 mg/kg group and patients receiving placebo. Note that two subjects are excluded from the 10 mg/kg ACZ885 because of missing data.

ISSN: 1478-6362